联合用药-话题@MedSci

#联合用药#

68篇内容 | 3389人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1514279, encodeId=1a5515142e9ec, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=Hepatology：研究确定新的联合用药方案，有望攻克肝癌耐药性！, objectType=article, longId=111695, objectId=4de11116957f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4de11116957f, replyNumber=0, likeNumber=76, createdTime=2017-09-03, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4de11116957f, moduleTitle=Hepatology：研究确定新的联合用药方案，有望攻克肝癌耐药性！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4de11116957f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514278, encodeId=b65515142e80e, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=Journal of Oncology Practice：一项对药物监测的前瞻性研究——癌症患者联合用药的药物间相互作用, objectType=article, longId=103324, objectId=bc181033241f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc181033241f, replyNumber=0, likeNumber=73, createdTime=2017-06-27, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc181033241f, moduleTitle=Journal of Oncology Practice：一项对药物监测的前瞻性研究——癌症患者联合用药的药物间相互作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc181033241f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514277, encodeId=e1ee15142e75a, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=Lancet：托法替尼单药或联合用药用于类风湿关节炎IIIb/IV期临床研究, objectType=article, longId=102279, objectId=cc361022e9ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc361022e9ce, replyNumber=0, likeNumber=63, createdTime=2017-06-19, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc361022e9ce, moduleTitle=Lancet：托法替尼单药或联合用药用于类风湿关节炎IIIb/IV期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc361022e9ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514276, encodeId=c45215142e68a, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=JCO：阿扎胞苷单药或与来那度胺或伏立诺他联合用药治疗高风险骨髓增生异常综合征或慢性单核细胞白血病, objectType=article, longId=98626, objectId=ca039862681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca039862681, replyNumber=0, likeNumber=66, createdTime=2017-05-14, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca039862681, moduleTitle=JCO：阿扎胞苷单药或与来那度胺或伏立诺他联合用药治疗高风险骨髓增生异常综合征或慢性单核细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca039862681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514275, encodeId=896f15142e5db, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=Lancet Respir Med：埃罗替尼与贝伐单抗联合用药使非小细胞肺癌T790M突变患者获益, objectType=article, longId=98017, objectId=688e9801ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=688e9801ee7, replyNumber=0, likeNumber=81, createdTime=2017-05-07, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=688e9801ee7, moduleTitle=Lancet Respir Med：埃罗替尼与贝伐单抗联合用药使非小细胞肺癌T790M突变患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=688e9801ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514274, encodeId=1ee515142e4e8, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=ACCR年会：联合用药提高PARP抑制剂在耐药卵巢癌中的应答, objectType=article, longId=94582, objectId=a8609458271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8609458271, replyNumber=0, likeNumber=55, createdTime=2017-04-05, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8609458271, moduleTitle=ACCR年会：联合用药提高PARP抑制剂在耐药卵巢癌中的应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8609458271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514273, encodeId=4e8315142e3fc, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=Diabetes Care：非2型糖尿病超重和肥胖患者Canagliflozin和芬特明联合用药效果如何？, objectType=article, longId=91797, objectId=034891e9757, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=034891e9757, replyNumber=0, likeNumber=32, createdTime=2017-03-16, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=034891e9757, moduleTitle=Diabetes Care：非2型糖尿病超重和肥胖患者Canagliflozin和芬特明联合用药效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=034891e9757)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514272, encodeId=955b15142e216, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=为什么阿奇霉素和头孢不能联合用药？, objectType=article, longId=83944, objectId=9e8683944cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e8683944cd, replyNumber=0, likeNumber=64, createdTime=2016-12-11, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e8683944cd, moduleTitle=为什么阿奇霉素和头孢不能联合用药？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e8683944cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514271, encodeId=58a215142e1fc, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=2016EBF建议——生物分析中联合用药和干扰测试发布, objectType=article, longId=78693, objectId=a6c7e869357, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6c7e869357, replyNumber=0, likeNumber=41, createdTime=2016-09-29, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6c7e869357, moduleTitle=2016EBF建议——生物分析中联合用药和干扰测试发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6c7e869357)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514270, encodeId=327015142e0aa, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=阿斯利康将携手Peregrine展开PD-L1抑制剂durvalumab联合用药研究, objectType=article, longId=70377, objectId=eb3fe037703, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb3fe037703, replyNumber=0, likeNumber=117, createdTime=2016-06-11, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb3fe037703, moduleTitle=阿斯利康将携手Peregrine展开PD-L1抑制剂durvalumab联合用药研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb3fe037703)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514269, encodeId=bad2151426940, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=NEJM：联合用药改善囊性纤维化蛋白质不足, objectType=article, longId=54182, objectId=0bf954182a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bf954182a8, replyNumber=0, likeNumber=52, createdTime=2015-07-31, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bf954182a8, moduleTitle=NEJM：联合用药改善囊性纤维化蛋白质不足, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bf954182a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514268, encodeId=c294151426820, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=Cancer Cell：新型联合用药对癌细胞有显著疗效, objectType=article, longId=53404, objectId=d0b753404a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0b753404a3, replyNumber=0, likeNumber=63, createdTime=2015-07-17, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0b753404a3, moduleTitle=Cancer Cell：新型联合用药对癌细胞有显著疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0b753404a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514267, encodeId=8308151426eb8, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期, objectType=article, longId=48932, objectId=982548932ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=982548932ef, replyNumber=0, likeNumber=66, createdTime=2015-04-04, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=982548932ef, moduleTitle=NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=982548932ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514266, encodeId=42da1514266a3, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=Lancet：新联合用药手段治疗HCV-4感染效果理想, objectType=article, longId=48891, objectId=336848891d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=336848891d5, replyNumber=0, likeNumber=78, createdTime=2015-04-03, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=336848891d5, moduleTitle=Lancet：新联合用药手段治疗HCV-4感染效果理想, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=336848891d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514265, encodeId=91ea151426567, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=JAMA：联合用药治疗HIV、HCV共感染, objectType=article, longId=48834, objectId=b1fa4883448, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1fa4883448, replyNumber=0, likeNumber=94, createdTime=2015-04-02, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1fa4883448, moduleTitle=JAMA：联合用药治疗HIV、HCV共感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1fa4883448)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514264, encodeId=d2e4151426447, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=Lancet Oncol：索拉菲尼+依维莫司联合用药治疗骨肉瘤未达到预期治疗效果, objectType=article, longId=45554, objectId=db84455542a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db84455542a, replyNumber=0, likeNumber=60, createdTime=2015-01-17, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db84455542a, moduleTitle=Lancet Oncol：索拉菲尼+依维莫司联合用药治疗骨肉瘤未达到预期治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db84455542a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514263, encodeId=d227151426322, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=痛风患者通过联合用药降低血清尿酸, objectType=article, longId=45538, objectId=af7b45538c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af7b45538c3, replyNumber=0, likeNumber=83, createdTime=2015-01-17, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af7b45538c3, moduleTitle=痛风患者通过联合用药降低血清尿酸, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af7b45538c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514262, encodeId=690f151426250, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=Clin Cancer Res：联合用药治疗胸腺上皮肿瘤效果显著, objectType=article, longId=42229, objectId=b953422298d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b953422298d, replyNumber=0, likeNumber=72, createdTime=2014-11-08, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b953422298d, moduleTitle=Clin Cancer Res：联合用药治疗胸腺上皮肿瘤效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b953422298d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514261, encodeId=444815142614d, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=The Lancet Oncology：来拉度胺和利妥昔单抗联合用药对惰性非霍奇金淋巴瘤具有较好的耐受性, objectType=article, longId=41415, objectId=a59e41415cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a59e41415cb, replyNumber=0, likeNumber=62, createdTime=2014-10-19, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a59e41415cb, moduleTitle=The Lancet Oncology：来拉度胺和利妥昔单抗联合用药对惰性非霍奇金淋巴瘤具有较好的耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a59e41415cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1514260, encodeId=abec151426000, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, objectTitle=IJC：丁健等mTOR激酶抑制剂联合用药研究获进展, objectType=article, longId=34349, objectId=fa5834349bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa5834349bb, replyNumber=0, likeNumber=70, createdTime=2014-05-08, rootId=0, userName=ms4964546379600229, userId=36f510649899, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa5834349bb, moduleTitle=IJC：丁健等mTOR激酶抑制剂联合用药研究获进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa5834349bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合用药

2020-05-29

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

Hepatology：研究确定新的联合用药方案，有望攻克肝癌耐药性！

2017-09-03

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

Journal of Oncology Practice：一项对药物监测的前瞻性研究——癌症患者联合用药的药物间相互作用

2017-06-27

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

Lancet：托法替尼单药或联合用药用于类风湿关节炎IIIb/IV期临床研究

2017-06-19

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

JCO：阿扎胞苷单药或与来那度胺或伏立诺他联合用药治疗高风险骨髓增生异常综合征或慢性单核细胞白血病

2017-05-14

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

Lancet Respir Med：埃罗替尼与贝伐单抗联合用药使非小细胞肺癌T790M突变患者获益

2017-05-07

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

ACCR年会：联合用药提高PARP抑制剂在耐药卵巢癌中的应答

2017-04-05

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

Diabetes Care：非2型糖尿病超重和肥胖患者Canagliflozin和芬特明联合用药效果如何？

2017-03-16

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

为什么阿奇霉素和头孢不能联合用药？

2016-12-11

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

2016EBF建议——生物分析中联合用药和干扰测试发布

2016-09-29

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

阿斯利康将携手Peregrine展开PD-L1抑制剂durvalumab联合用药研究

2016-06-11

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

NEJM：联合用药改善囊性纤维化蛋白质不足

2015-07-31

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

Cancer Cell：新型联合用药对癌细胞有显著疗效

2015-07-17

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期

2015-04-04

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

Lancet：新联合用药手段治疗HCV-4感染效果理想

2015-04-03

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

JAMA：联合用药治疗HIV、HCV共感染

2015-04-02

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

Lancet Oncol：索拉菲尼+依维莫司联合用药治疗骨肉瘤未达到预期治疗效果

2015-01-17

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

痛风患者通过联合用药降低血清尿酸

2015-01-17

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

Clin Cancer Res：联合用药治疗胸腺上皮肿瘤效果显著

2014-11-08

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

The Lancet Oncology：来拉度胺和利妥昔单抗联合用药对惰性非霍奇金淋巴瘤具有较好的耐受性

2014-10-19

ms4964546379600229 (审核中...)

前往app查看评论内容

#联合用药#

IJC：丁健等mTOR激酶抑制剂联合用药研究获进展

2014-05-08

科室
- - 订阅+
  - 更多科室
工具
服务